| Sanguine
Corporation is a public company (OTC BB: SGNC) based in Pasadena, California, whose
primary focus is the development of PHER-O2, a perfluorocarbon
(PFC) emulsion with oxygen carrying properties that has immediate applications as an
intravenous supplement to red blood cell function. The broad-based medical applications of
PHER-O2 have strong market potential. Sanguine is a well-established organization with
experts in the field of synthetic blood chemistry and development. Dr. Thomas C. Drees was
a leader in the creation of FluosolŪ, the only synthetic blood supplement approved to
date for human use by the United States Food and Drug Administration (FDA). The FDA
approved Fluosol for angioplasty use only in 1989 but Fluosol was withdrawn from the
market in 1994 because of the difficulty of storing it frozen and then bringing it to
ambient temperature prior to use. |
|
Of the
approximately 15,000 uses per year for the three full years it was on the market, fully
50% of Fluosol use was for “off label” adaptation to transfusions other than
angioplasty. Sanguine’s immediate goal is to accelerate development and test of the
Red Blood Cell (RBC) supplement PHER-O2, ultimately leading to FDA approval. To assist in
achieving this goal, a Medical Advisory Board (MAB) composed of scientists and physicians
has been established to advise Sanguine management on medical and scientific issues. These
include new product research, development, test, and applications of PFC emulsions. |
| Sanguine Corporation
101 East Green Street, Suite 6
Pasadena, California 91105
info@sanguine-corp.com
Contact:
Investor and Public Relations
Michael Dancy
M. E. Dancy & Associates Inc.
455 East 500 South Ste.205
Salt Lake City, Utah 84111
Ph: 801-746-3570
Fax: 801-532-1765
medancy@allwest.net |
|
|
